Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mCapOX + Cetuximab vs mFOLFOX6 + Cetuximab in Left-sided RAS/BRAF wt mCRC
NCT05022030Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2021
- Primary completion
- Jun 2025
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in colorectal cancer (CRC), sponsored by West China Hospital of Sichuan University. Started Jul 2021; status: recruiting.
02
Drugs
capecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05022030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05022030.